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researches have indicated that children are more susceptible to developing DHF than adults. [2, 12, 18, 19] It has been observed that different dengue serotypes, and even strains of the same serotype, differ in their propensity to cause severe disease. [20, 21] Many Indian studies on the clinical and laboratory profile of dengue patients had been done on serologically positive patients. As serological diagnosis demands a collection of samples 5 days post onset of illness, it usually depicts the manifestations occurring in the convalescent phase of disease. As severe complications related to dengue may occur very early in disease, it is important to explore the prognostic markers of severe disease during acute phase of disease in the first 5 days of illness.
The hyperendemicity with co-infection of two or more serotypes during the same time period has been widely suspected as one of the major causes of disease severity in dengue patients in India. [12, 13] Various studies have tried to establish a connection between causative serotype and disease outcome, but a definite link between distinct serotypes and severe manifestations has not been established yet. Small sample sizes, lack of all the four serotypes, inconsistencies in findings and short study durations are weaknesses of these studies.
The recent (2009) WHO classification of dengue is more competent in diagnosing severe cases which were missed earlier if classified using traditional (1997) classification. [22] None of the studies have been done so far to correlate dengue serotypes with the severity of dengue cases as per the recent WHO classification (2009) in India.
The objectives of our study are to identify prevalent dengue serotypes and to correlate the severity of dengue with the DENV serotypes in target population as per the recent WHO classification (2009).
subjEcts anD mEtHODs
A retrospective observational study was conducted after obtaining permission from the institutional review board of a tertiary care hospital in Gujarat. This study was carried out over a period of 1 year from 1 st January 2015 to 31 st December 2015.
A total of 242 dengue NS-1 antigen ELISA-positive cases were enrolled in the study. Non-haemolysed, non-turbid and non-lipaemic samples having adequate volume of at least 1 ml were selected. All the samples were tested for serotyping by dengue reverse-transcriptase-polymerase chain reaction (RT-PCR).
A conventional reverse transcriptase-PCR was performed. The protocol for PCR-based dengue serotyping is summarised as follows.
Viral RNA isolation
RNA isolation was performed using QIAmp Viral RNA mini kit (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. A total of 140 µL of serum was taken. In this method, 560 µl of AVL buffer (Qiagen, Valencia, CA) was taken and mixed thoroughly to yield a homogeneous solution. The solution was incubated at room temperature (15°C-25°C) for 10 min for lysis. This was followed by a brief centrifugation. RNA precipitation was done using 560 µl of ethanol (96%-100%) to the sample and mixing by pulse-vortexing for 15 s. The mixture was then transferred to QIAamp ® Mini column for RNA isolation. The Final RNA was eluted in 60 µL of the elution buffer.
cDNA synthesis
cDNA synthesis was performed using high-capacity cDNA Reverse Transcription Kit (Applied Biosystem, Foster city, CA, USA). Single-stranded cDNA was made using dengue-specific primers (D1 and D2). For this purpose, 10 µl of RNA was taken and RT Master Mix (Applied Biosystem, Foster city, CA, USA) was prepared according to the manufacturer's protocol. Reaction is set on thermocycler according to the temperature cycle summarised in Table 1 .
Dengue serotyping
Dengue serotyping was performed using the cDNA synthesised from the above step. cDNA (1:10-diluted cDNA) was taken as the template for the second round of PCR using DENV type-specific primers mentioned in Table 2 . Ts1,Ts2, Ts3 and Ts4 primers were used for DENV-1, DENV-2, DENV-3 and DENV-4 respectively. The PCR was performed using Qiagen TopTaq Master Mix (Qiagen, Valencia, CA, USA).
PCR conditions were as follows: 94°C for 2 min, 35 cycles of denaturation at 94°C for 30 s, annealing 55°C for 1 min, 72°C for 1 min and final extension at 72°C for 7 min. Amplicons were visualised on a 2% agarose gel. The results are interpreted in Table 3. PCR-confirmed-positive patients' demographic and clinical details were collected from the patient records and test requisition forms. 
Dengue without warning signs (D)
Fever and two of the following: • Nausea, vomiting • Rash • Aches and pains • Leukopenia • Positive tourniquet test.
Dengue with warning signs (DW)
It is defined as above with any of the following: • Abdominal pain or tenderness • Persistent vomiting • Clinical fluid accumulation (ascites, pleural effusion) • Mucosal bleeding • Lethargy, restlessness • Liver enlargement more than 2 cm • Laboratory: Increase in HCT concurrent with rapid decrease in platelet count.
Severe dengue
Dengue with at least one of the following criteria:
• Severe plasma leakage leading to • Shock (DSS) • Fluid accumulation with respiratory distress • Severe bleeding as evaluated by clinician • Severe organ involvement • Liver: aspartate transaminase or alanine transaminase ≥ 1000 • CNS: Impaired consciousness • Failure of heart and other organs.
Data were entered into Microsoft Excel 2007 sheets and analysed with IBM SPSS Statistics 21 software (IBM, New York, USA). Descriptive statistics were used to describe the studied variables.
rEsults
On the basis of RT-PCR, dengue infection was confirmed in 135 (55.78%) patients. Serotype characterisation was identified and shown in Table 4 . DEN-3 serotype was the most common infection in 71 (52.6%) patients, followed by DEN-2 serotype with 44 (32.6%) patients. Co-infection with two serotypes was found in 14 (8.94%) patients. The most common co-infection pattern found was DEN-2 and DEN-3 serotypes in 10 (7.4%) patients [ Table 4 ].
We found that male patients (83 [61.48%]) were affected more compared to female patients (52 [38.51%]). Gender-stratified distribution of dengue serotypes is shown in Table 4 . The most common age group affected was 21-30 years, with 55 (40.74%) cases. Detailed age-stratified distribution of dengue serotypes is shown in Table 5 .
We found that 88 (65.18%) dengue patients had presented with 2 and 3 days' duration from the onset of illness. Co-infection with more than one serotype was not noted after 3 days' duration from the onset of illness [ Table 6 ].
Majority of the cases (87.40% [n = 118]) were in the mildest category of dengue without warning signs in all serotype infections. About 2.22% (n = 3) cases of DEN-2 and 2.96% (n = 4) cases of DEN-3 were found in the category of dengue with warning signs. Severe dengue (SD) category had 2.22% (n = 3) cases of DEN-2 and 5.18% (n = 7) cases of DEN-3 serotypes. None of the serotype co-infection was found to fall in the categories of dengue with warning signs and SD [ Table 7 ].
All dengue cases with each serotype infection and co-infection presented with fever (100% [n = 135]). Headache, myalgia, joint pain, skin rash, conjunctival suffusion and haemorrhagic manifestations were found most commonly in DEN-3 serotype followed by DEN-2 serotype. Atypical presentations such as neurological features, persistent vomiting and cough were also found in only DEN-3 followed by DEN-2 serotype [ Table 8 ].
Data for platelet count were available in 92 patients from the records out of 135 cases. We found platelet count to be <100,000/cmm (thrombocytopenia) in 10 (10.86%) cases. It is most commonly found in DEN-3 serotype followed by DEN-2 serotype [ Table 9 ].
DiscussiOn
This study provided direct evidence for the presence of all four serotypes in this geographical region, with DEN-3 followed by DEN-2 as two predominant serotypes. This finding is very similar to a study conducted by Kumaria in India where DEN-2 and DEN-3 serotypes were most predominant. [23] Co-infection with two serotypes was observed in our study, with the most common co-infection pattern being DEN-2 and DEN-3 serotypes. In contrast to the situation in Latin American countries, where a single DENV serotype tends to predominate, in India, dengue is hyperendemic and all DENV serotypes circulate during the same period of time. [12, 13, 24] Due to this epidemiologic situation in Latin America where only one serotype is predominant at a time, it is easy to compare the clinical profiles of dengue cases in two time periods. Unfortunately, this task is more difficult in India where two or more serotypes are prevalent at a time.
A male preponderance (61.48%) was noted in the present study. This is comparable to studies by Patankar et al., Durani et al. and Jain et al., showing incidence in male patients of 65%, 70.79% and 60%, respectively. [25] [26] [27] This may be attributed to the high exposure of males to the bite of vector Aedes aegypti, due to their clothing habits or outdoor activities. A majority of cases were observed in the age group of 21-30 years. This is comparable to studies by Patankar et al. and Durani et al. This age group is highly exposed to external environment and mosquito vectors. Affection of the young also results in economic non-productivity. The high number of cases in young age groups implies that the disease is endemic in this region.
Majority of the dengue patients were noted within 5 days' duration from the onset of illness. As severe complications of dengue may occur at a very early stage in disease, it is important to explore the prognostic markers of severe disease during the acute phase of disease in the first 5 days of illness.
As per the recent (2009) WHO classification for severity of dengue, only DEN-3 and DEN-2 serotype cases were in the category of dengue with warning signs and SD. Earlier analyses of data collected during various DF and DHF outbreaks worldwide have shown associations of DENV-2 and DENV-3 with an increased risk of hospitalisation and severe disease. [10, 11, 13, 21, 28, 29] We have noted no case in dengue with warning signs or SD categories in any of the co-infections. It should be kept in mind that the particular sequence of infecting DENV serotypes can also influence the severity of disease. [10, 12] As different serotypes have circulated throughout the past years in the region, previous infections could very well have influenced the clinical manifestations of the current infection. It is a known fact now that secondary infection was associated with an increased severity of DENV infections. An extensive retrospective serological study evaluating neutralising antibodies to previous infections would best address this question, although this analysis would likely be hampered by the difficulty of ascertaining prior infections due to cross-reacting neutralising antibody responses in secondary infections. [30] The absence of severe cases in serotype co-infection also suggests simultaneous transmission of both the serotypes at the same time.
Headache, myalgia, joint pain, skin rash, conjunctival suffusion and haemorrhagic manifestations were found most commonly in DEN-3 serotype followed by DEN-2 serotype. This finding is in contrast to the findings of the study done by Kumaria where haemorrhagic manifestations were more common in DEN-4 serotype. However, in their study, DEN-4 positivity remained very low, and hence recommended more studies be done to validate their findings in this regard. [23] Atypical presentations such as neurological features, persistent vomiting and cough were also found in DEN-3 followed by DEN-2 serotypes.
Thrombocytopenia is an important indicator for the determination of severity in dengue cases. Correlation of dengue serotypes with platelet count was only possible in 92 cases. In the present study, it was found in 10.86% cases.
A majority of such cases were noted in infection with DEN-3 serotype followed by DEN-2 serotype.
cOnclusiOns
DENV-3 and DENV-2 serotypes are prevalent in the region and are associated with a more serious clinical profile than other serotypes as per the recent (2009) WHO classification. Co-infection between various dengue serotypes was noted but not associated with serious clinical profile. These findings provide new data to better characterise the pathogenic potential of distinct DENV serotypes in human populations. guidance in serotype testing of dengue NS-1 antigen-positive cases.
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